MARKET

ZYME

ZYME

Zymeworks
NASDAQ
23.54
+0.41
+1.77%
After Hours: 23.54 0 0.00% 17:44 08/07 EDT
OPEN
24.10
PREV CLOSE
23.13
HIGH
24.76
LOW
23.18
VOLUME
578.11K
TURNOVER
--
52 WEEK HIGH
29.75
52 WEEK LOW
11.51
MARKET CAP
1.67B
P/E (TTM)
-17.2177
1D
5D
1M
3M
1Y
5Y
1D
Zymeworks (ZYME) Stock Rich Valuation Meets Widening Losses
Simply Wall St · 22h ago
Zymeworks price target raised to $32 from $31 at Truist
TipRanks · 1d ago
Zymeworks Is Maintained at Overweight by Wells Fargo
Dow Jones · 1d ago
Zymeworks Price Target Raised to $40.00/Share From $37.00 by Wells Fargo
Dow Jones · 1d ago
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40
Benzinga · 1d ago
Zymeworks Is Maintained at Buy by Truist Securities
Dow Jones · 1d ago
Zymeworks Price Target Raised to $32.00/Share From $31.00 by Truist Securities
Dow Jones · 1d ago
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32
Benzinga · 1d ago
More
About ZYME
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.